EOSINOPHILIC IMMUNE DYSFUNCTION
ACROSS INFLAMMATORY DISEASES

Eosinophilic granulomatosis with polyangiitis (EGPA)

Eosinophilic
asthma (EA)

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Eosinophilic
esophagitis (EoE)

Eosinophilic granulomatosis with polyangiitis (EGPA)

Hypereosinophilic
syndrome (HES)

WHAT IS EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)?

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disease characterized by eosinophil-rich granulomatous inflammation and small- and medium-sized blood vessel vasculitis.1

Symptoms of EGPA2,3

Symptoms of Eosinophilic Granulomatosis with Polyangiitis
Symptoms of Eosinophilic Granulomatosis with Polyangiitis

The prevalence of EGPA is 10.7 per million to 17.8 per million worldwide.1

 

THE ROLE OF EOSINOPHILIC IMMUNE DYSFUNCTION IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Although the etiology of EGPA is not completely understood, eosinophils have a role in disease pathogenesis.1

Eosinophil infiltration of tissues is at least partly responsible for the end-organ damage associated with EGPA.1

Role of Eosinophilic Immune Dysfunction in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Role of Eosinophilic Immune Dysfunction in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Adapted from Furuta S. Allergol Int. 2019.1

 

CLINICAL CONSEQUENCES OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

In the absence of treatment, the 5-year survival rate for patients with EGPA is approximately 25%.2,4
With prompt diagnosis and effective treatment, the 5-year survival rate is restored to approximately 90%.2,5

When patients have ≥1 of the following factors there is an increased mortality risk6

Clinical Consequences of Eosinophilic Granulomatosis with Polyangiitis
Clinical Consequences of Eosinophilic Granulomatosis with Polyangiitis

ASTRAZENECA IS COMMITTED TO DISCOVERING NEW WAYS TO TREAT EOSINOPHILIC IMMUNE DYSFUNCTION IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS.